Black Chokeberry for Health & Longevity - Quick Reference Sheet

Black Chokeberry for Health & Longevity

Created on 10/13/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Wonder 1.0 – Audit

Black chokeberry is a dark fruit eaten or taken as juice, powder, or extract, used for heart, metabolic, and longevity-related health. Individual studies report improved blood-vessel function and one measure of thinking speed, but pooled evidence finds no clear overall heart or metabolic benefit. Harms are few; stomach upset and added effects with some medicines remain possible. (Full Review)

Protocol

Extract amounts studied / Higher extract amount studied
90 mg, 150 mg, or 500 mg daily
90 mg and 150 mg as separate groups; 500 mg in a separate trial
Juice amount studied / Whole-fruit powder studied
300 mL juice + 3 g powder, or 10 g berry equivalent
Juice plus powder for 8 weeks; whole-fruit powder for 12 weeks
Timing
Daily with habitual meals
No best time of day established
Time to effect
Vascular function
12 weeks
Extract and whole-fruit powder trials
Psychomotor speed
24 weeks
90 mg extract daily trial
Metabolic markers
8 to 12 weeks
Blood pressure, glucose, and lipid measures repeated

Benefits

Contraindications
  • Known allergy to black chokeberry or related berries
  • Pregnant or breastfeeding
  • Scheduled for surgery whose clinician has stopped platelet-active supplements beforehand
Key Interactions
  • Blood-pressure medication (for example amlodipine, lisinopril)
  • Glucose-lowering medication (for example metformin, insulin)
  • Anticoagulant and antiplatelet medication (for example warfarin, apixaban, aspirin, clopidogrel)
  • Over-the-counter pain medication (for example aspirin, ibuprofen)
  • Other polyphenol or blood-pressure supplements (for example hibiscus, beetroot, grape-seed extract)
  • Trabectedin

Risk & Side Effects

  • Low: Additive Blood-Pressure Lowering; Additive Blood-Glucose Lowering; Muscle Breakdown During Trabectedin Treatment
  • Speculative: Gastrointestinal Intolerance; Bleeding Tendency

Monitoring

Marker Target Why
Blood pressure No established target — track change from the individual's own baseline Marker the intervention is expected to change; safety check with medication
Fasting blood glucose 70 to 99 mg/dL Marker the intervention is expected to change; safety check with glucose-lowering medication
Hemoglobin A1c No established target — track change from the individual's own baseline Marker the intervention is expected to change over trial-length periods
Total cholesterol No established target — track change from the individual's own baseline Marker the intervention is expected to change
LDL cholesterol No established target — track change from the individual's own baseline Marker the intervention is expected to change

Cadence: Baseline before starting, repeat at 8 to 12 weeks, then every 6 to 12 months if intake continues

Qualitative Assessment

  • Energy and afternoon alertness
  • Exercise recovery and muscle soreness
  • Digestive tolerance, including nausea or loose stool
  • Dizziness on standing, as a possible sign of lower blood pressure
  • Sleep quality